State of Wyoming Buys New Stake in Krystal Biotech, Inc. $KRYS

Key Points

• Wyoming purchased a new 4,767-share stake in Krystal Biotech during the second quarter, valued at approximately $1.77 million. Institutional investors collectively own 86.29% of KRYS.
• Analysts remain broadly bullish, with an average “Moderate Buy” rating and a consensus price target of $365.40. Recent upgrades and target increases came from Chardan Capital, Jefferies, Bank of America and Citigroup.
• Krystal Biotech reported quarterly EPS of $1.79, beating estimates of $1.70, while revenue reached $119.22 million. Shares opened at $332.27, with the stock trading between a 52-week range of $136.73 and $382.54.

State of Wyoming purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,767 shares of the company's stock, valued at approximately $1,772,000.

Several other institutional investors have also bought and sold shares of KRYS. Royal Bank of Canada raised its position in shares of Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company's stock valued at $294,000 after buying an additional 964 shares in the last quarter. AQR Capital Management LLC increased its stake in Krystal Biotech by 29.9% during the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company's stock worth $2,187,000 after acquiring an additional 2,792 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Krystal Biotech by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company's stock valued at $2,870,000 after purchasing an additional 688 shares during the period. Empowered Funds LLC bought a new stake in shares of Krystal Biotech in the 1st quarter valued at approximately $218,000. Finally, Cetera Investment Advisers lifted its stake in shares of Krystal Biotech by 107.9% in the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company's stock valued at $597,000 after purchasing an additional 2,255 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Wall Street Analyst Weigh In

KRYS has been the topic of several analyst reports. Chardan Capital raised Krystal Biotech to a "strong-buy" rating in a research report on Monday, August 3rd. Jefferies Financial Group restated a "buy" rating and issued a $474.00 price target on shares of Krystal Biotech in a research report on Monday, July 13th. Bank of America lifted their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a "buy" rating in a research note on Tuesday, July 14th. Citigroup boosted their price objective on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings raised shares of Krystal Biotech from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Krystal Biotech presently has an average rating of "Moderate Buy" and an average target price of $365.40.

Krystal Biotech Price Performance

Shares of KRYS opened at $332.27 on Friday. The firm has a market capitalization of $9.84 billion, a price-to-earnings ratio of 41.64 and a beta of 0.53. Krystal Biotech, Inc. has a 1-year low of $136.73 and a 1-year high of $382.54. The company has a 50-day moving average of $344.39 and a 200 day moving average of $299.25.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping analysts' consensus estimates of $1.70 by $0.09. The business had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 7.68 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In related news, EVP John Charles Thomas sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 51,642 shares of company stock worth $16,471,923. Company insiders own 13.10% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source